Anterior|Siguiente

El efecto del medicamento Huangqin en la regulación metabólica en el proceso de transformación inflamatoria de la colitis en cáncer colorrectal asociado a la colitis

  • role： First author第一作者
  • Affiliation：

    Heilongjiang University of Chinese Medicine， Harbin 150040，China

  • Email：18946239877@163.com
  • Introduction：左星博，在读硕士，从事表观遗传学及中药药理学研究，E-mail：18946239877@163.com
ZUO Xingbo1,  
  • Affiliation：

    Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences，Beijing 100700，China

FENG Xue2,  
  • Affiliation：

    Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences，Beijing 100700，China

ZHANG Caijuan2,  
  • Affiliation：

    Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences，Beijing 100700，China

LIU Haifan2,  
  • Affiliation：

    Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences，Beijing 100700，China

LIU Jianyao2,  
  • Affiliation：

    Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences，Beijing 100700，China

LIU Bin2,  
  • Affiliation：

    Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences，Beijing 100700，China

ZHU Lin2,  
  • Affiliation：

    Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences，Beijing 100700，China

SUN Qiyue2,  
  • role： Corresponding author通信作者
  • Affiliation：

    Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences，Beijing 100700，China

  • Email：wdf122644@126.com
  • Introduction：王敦方，博士，助理研究员，从事中药药理学研究，E-mail：wdf122644@126.com；
WANG Dunfang2*,  
  • role： Corresponding author通信作者
  • Affiliation：

    Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences，Beijing 100700，China

  • Email：wpyang@icmm.ac.cn
  • Introduction：杨伟鹏，博士，研究员，博士生导师，从事中药药理学研究，E-mail：wpyang@icmm.ac.cn
YANG Weipeng2*

resumen

El objetivo del estudio es explorar los mecanismos de intervención del HQT en el proceso de transformación inflamatoria del colon en cáncer (CAC) basado en la metabolómica no dirigida, métodos estadísticos de análisis multivariante. El análisis de la bioquímica de la diversidad metabólica mostró que el metabolismo del ácido linoleico y el tetrahidrocannabinol es la vía más perturbada del desarrollo de CAC. La fase de proliferación se caracteriza por la expansión de la red del metabolismo de los aminoácidos; en la etapa del tumor, surgieron dos nuevas rutas, el metabolismo del ácido nicotínico y el xantinol-rthandénin. El efecto del HQT se manifiesta por su intervención en la vía del ácido linoleico en la fase inflamatoria, por la corrección del desequilibrio del metabolismo de la colina-carnitina en la fase de proliferación, y en la etapa del tumor se hace especial hincapié en la inhibición del metabolismo de la nicotinamida y el triptófano. Conclusiones: El HQT tiene una regulación de las perturbaciones metabólicas en tres etapas del proceso de transformación de la inflamación colónica en cáncer, lo que ralentiza eficazmente el proceso de transformación de la inflamación colónica en cáncer. También revela la característica dinámica del metabolismo de la transformación de la inflamación en cáncer y propone un nuevo enfoque para estudiar objetivos farmacológicos de lucha contra los tumores basados en la reprogramación metabólica.

palabra clave

Medicamento Huangqin; transformación cancerosa; metabolómica; inflamación; proliferación

References

  1. 1.
    FERLAY J，STELIAROVA-FOUCHER E，LORTET-TIEULENT J，et al.Cancer incidence and mortality patterns in Europe：Estimates for 40 countries in 2012［J］.Eur J Cancer，2013，49（6）：1374-1403.
  2. 2.
    ANGELOU A，ANDREATOS N，ANTONIOU E，et al.A Novel modification of the AOM/DSS model for inducing intestinal adenomas in mice［J］.Anticancer Res，2018，38（6）：3467-3470.
  3. 3.
    CHEN X，HE S Q，LI W D.Effective therapeutic targets of traditional Chinese medicine for colorectal cancer based on its pathogenesis［J］.World Chin Med，2023，18（21）：3118-3124.
  4. 4.
    DEKKER E，TANIS P J，VLEUGELS J L A，et al.Colorectal cancer［J］.Lancet，2019，394（10207）：1467-1480.
  5. 5.
    YU F H，HUANG J，CHENG N，et al.Immune metabolic reprogramming：A new perspective of traditional Chinese medicine in the treatment of colon cancer［J］.Jiangxi J Tradit Chin Med，2023，54（9）：70-75.
  6. 6.
    NICOLINIA，FERRARIP.Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression，immune escape，and response to immunotherapy［J］.Front Immunol，2024，15：1353787.
  7. 7.
    WUZ D，ZUOM L，ZENGL，et al.OMA1 reprograms metabolism under hypoxia to promote colorectal cancer development［J］.EMBO Rep，2021，22（1）：e50827.
  8. 8.
    RADHAKRISHNAN S T，TRUST I C H N，MULLISH B H，et al.Deciphering the microbiome-metabolome landscape of an inflammatory bowel disease inception cohort［J］.Gut Microbes，2025，17（1）：2527863.
  9. 9.
    SIDEBOTTOM A M，CHANG E B.IBD microbial metabolome：The good，bad，and unknown［J］.Trends Endocrinol Metab，2020，31（11）：807-809.
  10. 10.
    ZAKERSKA-BANASZAK O，LADZIAK K，KRUSZKA D，et al.New potential biomarkers of ulcerative colitis and disease course：Integrated metagenomic and metabolomic analysis among Polish patients［J］.J Gastroenterol，2025，doi：.
  11. 11.
    WANG D Z，DUBOIS R N.The role of anti-inflammatory drugs in colorectal cancer［J］.Annu Rev Med，2013，64（1）：131-144.
  12. 12.
    BERTAGNOLLI M M，EAGLE C J，ZAUBER A G，et al.Celecoxib for the prevention of sporadic colorectal adenomas［J］.N Engl J Med，2006，355（9）：873-884.
  13. 13.
    YI C Q，SUN J N，ZHANG J J，et al.Study on Sijunzi decoction in rectifying digestive disorder in mice［J］.Chin J Integr Trad West Med，1997（1）：42-44.
  14. 14.
    JIANG Y F，HUANG Y，XIAO C，et al.Inhibitory effect and mechanism of Sishenwan-containing serum on aerobic glycolysis in human colon cancer cells［J］.Chin J Exp Tradit Med Form，2023，29（19）：26-33.
  15. 15.
    LAMW，BUSSOMS，GUANF L，et al.The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity［J］.Sci Transl Med，2010，2（45）：45ra59.
  16. 16.
    CHANGOUC A，SHIAHH S，CHENL T，et al.A phase Ⅱ clinical trial on the combination therapy of PHY906 plus capecitabine in hepatocellular carcinoma［J］.The Oncologist，2021，26（3）：e367-e373.
  17. 17.
    LIUS H，CHENGY C.Old formula，new Rx：The journey of PHY906 as cancer adjuvant therapy［J］.J Ethnopharmacol，2012，140（3）：614-623.
  18. 18.
    WANGD F，ZHUL，LIUH F，et al.Huangqin decoction alleviates colitis-associated colorectal cancer via amino acids homeostasis and PI3K/Akt/mTOR pathway modulation［J］.J Ethnopharmacol，2024，334：118597.
  19. 19.
    MAX R，WANGD F，LIUY Q，et al.Transcriptomics and experimental validation-based approach to understand the effect and mechanism of Huangqin decoction interfeience with colitis associated colorectal cancer［J］.Heliyon，2023，9（3）：e13739.
  20. 20.
    ZHU L，WANG D F，FENG X，et al.Effect of huangqin decoction on inflammation and short-chain fatty acid-related gut microbiota in mouse model of inflammation-associated colorectal cancer［J］.Chin J Exp Tradit Med Form，2024，30（23）：157-169.
  21. 21.
    ZHU L，WANG D F，FENG X，et al.Intervention mechanism of Huangqintang on intestinal inflammation and proliferation in colitis-associated colon cancer［J］.Chin J Exp Tradit Med Form，2023，29（22）：1-10.
  22. 22.
    LI T，ZHUANG S X，WANG Y W，et al.Flavonoid profiling of a traditional Chinese medicine formula of Huangqin Tang using high performance liquid chromatography［J］.Acta Pharm Sin B，2016，6（2）：148-157.
  23. 23.
    THAKER A I，SHAKER A，RAO M S，et al.Modeling colitis-associated cancer with azoxymethane （AOM） and dextran sulfate sodium （DSS）［J］.J Vis Exp，2012（67）：4100.
  24. 24.
    WIRTZ S，POPP V，KINDERMANN M，et al.Chemically induced mouse models of acute and chronic intestinal inflammation［J］.Nat Protoc，2017，12（7）：1295-1309.
  25. 25.
    WANG D F，ZHU L，LIU H F，et al.Altered gut metabolites and metabolic reprogramming involved in the pathogenesis of colitis-associated colorectal cancer and the transition of colon "inflammation to cancer"［J］.J Pharm Biomed Anal，2025，253：116553.
  26. 26.
    SUN R Q，ZHANG Y Y，ZHAO X，et al.Temporal and spatial metabolic shifts revealing the transition from ulcerative colitis to colitis-associated colorectal cancer［J］.Adv Sci，2025，12（11）：e2412551.
  27. 27.
    SUN Y D，HE Q，LI J J，et al.A GSTP1-mediated lactic acid signaling promotes tumorigenesis through the PPP oxidative branch［J］.Cell Death Dis，2023，14（7）：463.
  28. 28.
    LI G Z，WANG D，ZHAI Y，et al.Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma［J］.Cell Metab，2024，36（8）：1696-1710.e10.
  29. 29.
    JIN M R，WANG L，LI Y J.Effect of lactate on immune cells in tumor microenvironment and progress of related target therapy［J］.Cancer Res Prev Treat，2023，50（6）：634-640.
  30. 30.
    GUOX L，RENX，YANC，et al.Quantitative proteomics reveals the role of lysine lactylation in lenalidomide-resistance in multiple myeloma cells［J］.ACS Chem Biol，2025，20（7）：1728-1738.
  31. 31.
    LIUS Y，CHENY P，CHENJ，et al.ACACA depletion activates the cPLA2-arachidonic acid-NF-κB axis to drive inflammatory reprogramming in androgen receptor-independent prostate cancer［J］.Cell Commun Signal，2025，23（1）：352.
  32. 32.
    LIAOP，WANGW M，WANGW C，et al.CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4［J］.Cancer Cell，2022，40（4）：365-378.e6.
  33. 33.
    PLATTENM，NOLLENE A A，RÖHRIGU F，et al.Tryptophan metabolism as a common therapeutic target in cancer，neurodegeneration and beyond［J］.Nat Rev Drug Discov，2019，18（5）：379-401.
  34. 34.
    SHAO Z F，DING P J.Research progress on the role of dyslipidemia in the pathogenesis of colorectal cancer and its related therapeutic applications［J］.Shandong Med J，2020，60（32）：94-97.
  35. 35.
    LIT，LUOC T，LIUZ Y，et al.Nicotinamide mononucleotide protects STAT1 from oxidative stress-induced degradation to prevent colorectal tumorigenesis［J］.MedComm，2024，5（12）：e70006.

Leer el texto completo

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website